Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Citius Oncology, Inc. (CTOR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: CTOR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
0 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
Analysis of Past Performance
Type Stock | Historic Profit 121.35% | Avg. Invested days 51 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 105.18M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta -0.06 | 52 Weeks Range 0.55 - 40.50 | Updated Date 06/16/2025 |
52 Weeks Range 0.55 - 40.50 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.38 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -22.41% | Return on Equity (TTM) -93.64% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 108982029 | Price to Sales(TTM) - |
Enterprise Value 108982029 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 71552400 | Shares Floating 5503095 |
Shares Outstanding 71552400 | Shares Floating 5503095 | ||
Percent Insiders 95.08 | Percent Institutions 0.76 |
Upturn AI SWOT
Citius Oncology, Inc.
Company Overview
History and Background
Citius Oncology, Inc. is a late-stage biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on cancer care. Founded in 2014, the company has primarily focused on developing Mino-Lok and Halo-Lido, with Mino-Lok being their lead candidate.
Core Business Areas
- Anti-Infectives: Developing Mino-Lok, an antibiotic lock solution to salvage central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs).
- Oncology Supportive Care: Developing Halo-Lido, a novel formulation of halobetasol and lidocaine for the relief of hemorrhoids in cancer patients.
Leadership and Structure
Leonard Mazur is the Chairman and CEO. The company operates with a typical management structure including a CFO, CMO, and other functional heads.
Top Products and Market Share
Key Offerings
- Mino-Lok: Mino-Lok is an antibiotic lock solution in Phase 3 clinical trials aimed at salvaging infected central venous catheters. Market share data is not yet available as the product is not yet approved. Competitors include standard antibiotic treatments and catheter removal which has risk factors in itself. There is no direct competitor for Mino-Lok in the market. It has the potential to replace standard procedures and drugs if approved. Current revenue from this product is $0, as it is pre-commercialization.
- Halo-Lido: Halo-Lido is a topical formulation in Phase 2b clinical trials for hemorrhoid relief in cancer patients. Market share data is unavailable as the product is not yet approved. Competitors include topical steroids, analgesics, and surgical options for hemorrhoids. Current revenue from this product is $0, as it is pre-commercialization.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and significant market potential for successful products. There is a growing need for innovative therapies in oncology and anti-infectives.
Positioning
Citius Oncology is positioned as a late-stage biopharmaceutical company focused on niche markets with unmet needs in cancer care and anti-infectives. Their competitive advantage lies in their unique product candidates that address specific complications in cancer patients.
Total Addressable Market (TAM)
The TAM for catheter-related bloodstream infections and hemorrhoid relief is substantial, potentially reaching billions of dollars annually. Citius is focusing on specific patient populations within these markets, allowing them to target a more manageable segment initially.
Upturn SWOT Analysis
Strengths
- Late-stage product candidates (Mino-Lok in Phase 3)
- Focus on unmet medical needs
- Experienced management team
- Proprietary formulations with potential for patent protection
Weaknesses
- Reliance on successful clinical trial outcomes
- Limited revenue and profitability
- Dependence on external funding
- Concentrated product pipeline
Opportunities
- Potential regulatory approval for Mino-Lok and Halo-Lido
- Expansion into new indications or markets
- Strategic partnerships or collaborations
- Increasing prevalence of CRBSIs and hemorrhoids
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing treatments or new entrants
- Patent expirations
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- BMRN
- SCYX
- XBI
Competitive Landscape
Citius faces competition from established pharmaceutical companies and other biotechnology firms developing therapies for CRBSIs and hemorrhoids. Their success will depend on demonstrating superior efficacy, safety, and cost-effectiveness compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Citius Oncology's growth has been primarily through the development of its product pipeline. Growth in stock price has been driven by announcements of successful clinical trials.
Future Projections: Future growth is contingent on the successful commercialization of Mino-Lok and Halo-Lido. Analyst estimates vary depending on the likelihood of regulatory approval and market penetration.
Recent Initiatives: Recent initiatives include advancing Mino-Lok through Phase 3 clinical trials and Halo-Lido through Phase 2b clinical trials. The company is also actively seeking funding to support its development programs.
Summary
Citius Oncology is a promising late-stage biopharmaceutical company with a focus on unmet medical needs in cancer care. Their success is heavily reliant on the positive outcomes of their clinical trials and subsequent regulatory approvals. While the company faces financial risks due to its pre-revenue status, its innovative product candidates present significant potential for future growth. They need to navigate the regulatory landscape and clinical risks effectively to capitalize on their opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. The information provided is based on publicly available data and may be subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Citius Oncology, Inc.
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2022-12-08 | Chairman, CEO & President Mr. Leonard L. Mazur | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees - | Website |
Full time employees - | Website | ||
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.